Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes.... Almost 400k traded last 2 trades of the day. (Executed after closing)
Only if the FDA has Questions or comments that require the change of the initial package
I believe the timing of the diabetes presentation is both a function of being prepared to share the technology as well as a strategic fit.
Preparation takes a lot of time and Pmcb has been focused on pancreatic treatment and getting it to trial. The trail will also go along way to prove the efficacy of the diabetes treatment as the Magellan cells have already been proven, they just need the bio inert encapsulation.
For strategic purposes the timing is excellent. As we approach clinical trials potential buyers need to be aware of other applications of the technology to value it appropriately. Although the diabetes trial is likely not to commence anytime soon. It is very possible that the company who buys the pancreatic treatment or license will get it cheaper if they a free to finance future trials
Although I do I grew that it's possible a large pharma is holding this back, I think it is far more likely that there are large investor holdin the PPS down while they accumulate (an effort to accumulate as many shares as possible at an undervalued entry point) once the are done accumulating, they will release the selling pressure
Yes... Presentation title is "a cure for diabetes" or something like that
The quickest way for a company to be acquired is the "One Step" method. In this case, the bidder simply calls for a shareholder vote. If the shareholders approve the terms of the offer, the deal can go forward (excepting any legal or other impediments to the deal).
In the "Two-Step" method, which is the case with Dell, the bidder issues a "tender offer" which you mentioned, where the current shareholders can agree to sell their shares to the bidder, usually at a premium. If the bidder secures the acceptance of 90% of the shares, they can immediately go forward with what is called a "short form" merger, and can effect the merger without ever calling for a shareholder meeting or vote. Any stockholders that hold out and do not want to sell are "squeezed out" once the merger has been effected, but retain the right to redeem their outstanding shares at the valuation of the tender offer.
If shareholders controlling say 25% of the shares (not necessarily 25% of the shareholders) were to oppose the tender offer, there would be serveral alternatives. If the bidder did not have at least 51% of the shares secured, they would likely either increase the valuation of the tender offer, or choose to abandon the takeover. If the bidder had 51% or more of the shares secured, but not 90%, they could issue a proxy statement, call for a shareholder meeting and a vote to effect the merger. Or, they could increase the tender offer in order to try to secure 90% of the shares in order to effect the short form merger. If the bidder is able to secure even 51% of the shares, either through the proxy or by way of a controlling interest along with a consortium of other shareholders, they are able to effect the merger and squeeze out the remaining shareholders at the price of the tender offer (majority rules!).
The rise to .50 was pure Mjna hype.... Just collateral movement related to the Mjna pump.. Base on no news or progress.
I sold most of my shares at .4 and started buying again at .1.
This time it's different the PPS growth is based on progress and milestone completions. The timing is also way better so much closer to the trial MMs don't have a year plus to drag the price down
I totally agree for a company at the stage of pmcb. Although the charts do tell us what most of us already know from simply paying attention. But for new investors who have not been following along it is important. For example the golden cross 50/200 which is forming tells new investors and us that there is much stronger support at higher levels than there has been before. Very bullish
Couldn't agree more. 300k + is a very nice position to be holding right now. Never invest more than you are willing to lose in any pre revenue spec play.
Entry point won't matter much to anyone in 6 months to a year...if Pmcb performs
My average is .069... But it will be increasing over the next few months as I buy more at .12-.17
I know a few other pmcb investors with more than 10m, some post here from time to time. All of us look at this as a 2 year minimum.... Likely 5 or longer to maximize value.
Only reason I'd sell sooner is if I Envision faster returns of the same magnitude elsewhere.... But I like to be reasonably diversified with my spec investments
I have been buying for 4 years now haven't sold a share yet. I'm in this with 5m shares and have no plans of selling even after trials
I doubt it gets down to .10 again, but if it does I'm all in. I'm a buyer @.12 all next week
Investors have to register when they own more then 5% of a public company. This is visible to everyone. Furthermore investors who own more then 10% have to publicly file when they increase or decrease their position. They also have to declare whether or not it is their intent to gain majority control.
Because of this a hostile takeover is unlikely as these announcements would created a bidding war, and with several big pharmas potentially interested it would likely be easier and cheaper to negotiate for a buyout privately.
Hostile takeovers usually only occur when only one group sees value in acquiring a company due to liquidation value or synergies exclusive to the acquiring company
The date has not yet been announced
My guess is we see a late afternoon run. No one even the flippers want to risk missing the gap from the IND date being released
There is a 6 month hard stop for the trial, so the real question is the trial start date. My best guess is feb/mar giving results in July or August. Could be sooner
After IND submission the FDA has 30 days to make comments.... If no comments are sent after 30 days IND is granted in facto
Are we really complaining about $4500 a month in rent for office space?
It's just the paper work being processed... One of many ways MMs can manipulate...they do not have to process immediately. Could have not processed all the low trades till end of day to try to create further sell off
OTC do not trade after hours! Please watch video to understand what this is.
http://www.timothysykes.com/2012/07/do-otcbb-and-pink-sheet-penny-stocks-trade-premarket-or-afterhours-video-answer/
Nobody knows what's going to happen. It's about being comfortable with the risk. Don't invest what u are not willing to lose.i originally bought in at .09 and sold during the Mjna spike for . 43. Used profits to buy in again 4 x the shares @ .08.
I have 7m at .085. Price may continue to drop down to .05... But I'd get in now. The real risk here is not pps related... It's the Potential FDA approval or risk of not getting there.
If u buy in now and company Is successful you are not going to care about about a 5k cost difference. If the company fails u will loose 60k instead of $55k
At least we know they have become current on their fillings... Uoip vs uoipe
There are transitioning the rsplit... It will be up tomorrow
Of course, there is a lot of risk here, that's why it's 0.06 per share. If this gets to trials risk is reduced if it does well in trials risk is further reduced.
Pharma valuations treat risk like a discount rate on potential value... The market does as well
I believe that pmcb has already stuck a non equity deal to fund the PC trials in exchange for discounted licensing or right of first refusal.
I have expressed this opinion before so I am not going to lay out the logic again. U can see it in previous posts, but it involves the confidentiality agreements, the redesign of the test and principals relationship with celgene
Glad I could help
This is how virtually all biotech / consulting firms like McKinsey approach valuation of targeted licenses (some small differences) but this is the gist of it.
Just got sick of the debate.
Pharma Buyout valuation methodology
http://www.torreyapartners.com/documents/pharmaceutical-valuation-in-licensing-dec2013-torreya.pdf
Licensing not buyout
Just my opinion but here are my thoughts as to why.
We know Confidentiality agreements were signed. My speculation as to the reasoning for this is that a company got preferred pricing on the licensing and possibly an exclusive for the pancreatic treatment (for a short time) in exchange for funding of other trials. Under the SEC regulations this type of agreement would be eligible for confidential treatment because the licensing price given would not represent the market price to other companies due to the exchange for funding of other clinical trials.
Secondly, we redesigned the pancreatic trial as to not compete with celgene's current gold standard. This was likely part of the negotiation above to preserve celgene's gold standard revenue for the time being. I think that this was An arbitrage move by celgene, and they likely promised a significant amount to fund the diabetes treatment to protect their current position in the pancreatic Market.
Vonhoff's and others relationship with celgene further supports this theory.
IMO, if this is the case, it is a brilliant move for both parties.
Celgene would protect there gold standard and get discounted licensing for instances where their gold standard is no longer effective (and likely the future gold standard)
PMCB, would get funding for the diabetes trials (a much larger market) without having to take on debt or take on significant dilution or have to sell the pancreatic treatment to fund other trials. Secondly, they would receive licensing revenues for a currently unmet need.
Thoughts and opinions are welcome
Be patient and save to by on the dips or when consolidating. IMHO we have 3-4 months before this jumps to the next level, until then pps will fluctuate between 5 and 8 cents
Just wanted to be clear that most of us are not underwater. And see real potential here
In educated investors.... The stock went from .2tob.6 in 2 days with no news except for an mmj industry pump ... Mmj is a tiny part of pmcb... Not even quantifiable. Diabetics is why I'm here
I have more than 8m shares At an average cost of $0.082. Back when the price shot up to $0.6+ I had about 2m shares.... I sold half of them because I recognized it was an Mjna spike and had nothing to do with this company. I used the some of the proceeds to build my position. Next time this spikes on the companies merit.... It up for good. Good luck getting a single share out of my hands in the next 5 years... Maybe sell a small position at some a $3+
All of this noise over the pps fluctuation is reduce loud. Whether it's manipulation, tax sell off, or anything else.... It does not change the future value of the company.
The future value is speculative based on your dd and where you think it fits In The market, but pps does not change that.
If you are a trader ... Get some shares and make 50% pretty quickly.
If you are a real long but more shares or don't. Your pay day is a year out minimum even if there is a buyout I'm holding long
I understand that but it's a self fulfilling prophecy.... They suggested selling then before the even new of any wrong doing or even began there investigation.
If they had told me that Pmcb was guilty of violating section 10b than maybe... But they didn't even know that. Basically tried to convince me to sell on s rumor of a violation that they had no further information on
I contacted them just for sport... Knowing that it was likely nothing. They said that they are in the early stages of investigation.
Really had nothing to tell me.
But more interestingly said that if i sold my shares I could potentially recoup damages... But not until I sell.
I found that to be very fishy